29274-13-3Relevant articles and documents
In silico design of novel probes for the atypical opioid receptor MRGPRX2
Lansu, Katherine,Karpiak, Joel,Liu, Jing,Huang, Xi-Ping,McCorvy, John D.,Kroeze, Wesley K.,Che, Tao,Nagase, Hiroshi,Carroll, Frank I.,Jin, Jian,Shoichet, Brian K.,Roth, Bryan L.
, p. 529 - 536 (2017)
The primate-exclusive MRGPRX2 G protein-coupled receptor (GPCR) has been suggested to modulate pain and itch. Despite putative peptide and small-molecule MRGPRX2 agonists, selective nanomolar-potency probes have not yet been reported. To identify a MRGPRX
Evaluation of novel 7-(hetero)aryl-substituted pyrazolo[1, 5-a]pyrimidines as phosphodiesterase-4 inhibitors
Kodimuthali Arumugam,Gupta, Rajesh,Parsa, Kishore Venkata Laxmi,Prasunamba, Padala Lakshmi,Pal, Manojit
scheme or table, p. 402 - 408 (2011/10/18)
A novel series of 7-(hetero)aryl substituted-pyrazolopyrimidines, prepared via an AlCl3 induced C-C bond forming reaction of 7-chloro-5-phenyl-pyrazolo[1,5-a]pyrimidine with arenes and heteroarenes have been investigated as PDE4 inhibitors. Amo
PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
-
Page/Page column 34, (2008/06/13)
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.